Free Trial

David Stanton Analyst Performance

Analyst at Jefferies Financial Group

David Stanton is a stock analyst at Jefferies Financial Group, covering 2 publicly traded companies across a range of sectors. While full access to David Stanton's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Stanton's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
2 Last 3 Years
Buy Recommendations
0.00% 0 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy0.0%0 ratings
Hold100.0%2 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Hold recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
50.0% of companies on NASDAQ
1 company
OTCMKTS
50.0% of companies on OTCMKTS
1 company

David Stanton, an analyst at Jefferies Financial Group, currently covers 2 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

David Stanton of Jefferies Financial Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
1 company
50.0%
MEDICAL SERVICES
1 company
50.0%

David Stanton's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Mesoblast Limited stock logo
MESO
Mesoblast
7/18/2025Downgrade$12.34Hold